Shots:

• The EC has approved Nyvepria- a biosimilar referencing Neulasta to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic CT for malignancy
• The EC approval is based data demonstrating a high degree of similarity of Nyvepria to its reference product
• Pfizer plans to make Nyvepria available to patients in multiple EU countries starting in Q1’21. The EC’s approval follows the US FDA’s approval granted in Jun’2020

­ Ref: Pfizer | Image: Pfizer